← Leaderboards
Ronald M Krauss
University Of Calif-Lawrenc Berkeley Lab
$47,051,548
Attributed
$54,636,182
Total exposure
15
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5M · FY2005–20$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$72,323,855 · 17
By mechanism
U01$25,381,479 · 2
P50$14,868,821 · 2
U19$12,841,916 · 1
R01$9,428,854 · 2
P01$4,017,974 · 2
RF1$2,999,547 · 1
Top collaborators
- Nathalie Bergeron9 shared
- Aldons Jake Lusis7 shared
- Marisa Wong Medina6 shared
- Howard L Mcleod4 shared
- Alison Motsinger-Reif4 shared
- Tim Wiltshire2 shared
- Medellena Maria Glymour1 shared
- Catherine Ann Schaefer1 shared
Most similar at University Of Calif-Lawrenc Berkeley Lab
Same institution · by research overlap
- Patricia Blanche$358,919
Others in their field
Top investigators on “Cardiovascular Disorder Risk”
- Chanza Baytop · Westat, Inc.$271,217,917
- David M Nathan · Massachusetts Institute Of Technology$139,971,113
- John M Lachin · George Washington University$134,552,372
- Richard A Gibbs · Baylor College Of Medicine$67,454,169
- Marinella Temprosa · George Washington University$60,714,123
- Rose A Gubitosi-Klug · Case Western Reserve University$60,452,599
Research focus
Cardiovascular Disorder RiskLipidsBaseGeneticCardiovascular DiseasesResponsePharmacogenomicsGenotypeGenesVariantLow-Density LipoproteinsPharmaceutical PreparationsCohortPhenotypeResearch PersonnelMetabolicAdverse EventClinical TrialsCandidate Disease GeneLeadGenome Wide Association StudyGenetic VariantAfrican AmericanPrograms
Grant awards (64)
Statin Treatment and Incident Alzheimer's Disease and Related Dementias in a Large, Multi-ethnic Health Plan$2,999,547
RF1 · FY2020 · AG
Pharmacogenomics of Statin Therapy$1,524,688
P50 · FY2019 · GM · contact PI
Pharmacogenomics of Statin Therapy$1,173,979
P50 · FY2019 · GM · contact PI
Administrative Core - Pharmacogenomics of Statin Therapy (POST)$172,551
P50 · FY2019 · GM · contact PI
Pharmacogenomics of Statin Therapy$2,667,664
P50 · FY2018 · GM · contact PI
Phamarcogenomics of Statin Therapy (SUPPLEMENT)$395,986
P50 · FY2018 · GM · contact PI
Administrative Core - Pharmacogenomics of Statin Therapy (POST)$162,263
P50 · FY2018 · GM · contact PI
Pharmacogenomics of Statin Therapy$2,688,571
P50 · FY2017 · GM · contact PI
Administrative Core - Pharmacogenomics of Statin Therapy (POST)$162,243
P50 · FY2017 · GM · contact PI
Pharmacogenomics of Statin Therapy$2,741,022
P50 · FY2016 · GM · contact PI
Administrative Core - Pharmacogenomics of Statin Therapy (POST)$175,325
P50 · FY2016 · GM · contact PI
Pharmacogenomics of Statin Therapy$2,836,708
P50 · FY2015 · GM · contact PI
Saturated Fat and Protein Effects on Atherogenic Dyslipidemia$1,387,413
R01 · FY2015 · HL · contact PI
Genetic Etiology of Cancer Drug Response$396,756
R01 · FY2015 · CA
Administrative Core - Pharmacogenomics of Statin Therapy (POST)$167,821
P50 · FY2015 · GM · contact PI
Pharmacogenomics and Risk of Cardiovascular Disease$2,555,469
U19 · FY2014 · HL · contact PI
Saturated Fat and Protein Effects on Atherogenic Dyslipidemia$1,475,328
R01 · FY2014 · HL · contact PI
Genetic Etiology of Cancer Drug Response$454,879
R01 · FY2014 · CA
Saturated Fat and Protein Effects on Atherogenic Dyslipidemia$169,697
R01 · FY2014 · HL · contact PI
Pharmacogenomics and Risk of Cardiovascular Disease$2,457,795
U19 · FY2013 · HL · contact PI
Saturated Fat and Protein Effects on Atherogenic Dyslipidemia$1,436,341
R01 · FY2013 · HL · contact PI
Genetic Etiology of Cancer Drug Response$446,811
R01 · FY2013 · CA
Genetic and Molecular Approaches To Cardiovascular Disease$210,296
T32 · FY2013 · HL · contact PI
Pharmacogenomics and Risk of Cardiovascular Disease$2,584,979
U19 · FY2012 · HL · contact PI
Saturated Fat and Protein Effects on Atherogenic Dyslipidemia$1,504,126
R01 · FY2012 · HL · contact PI
Genetic Etiology of Cancer Drug Response$500,082
R01 · FY2012 · CA
Genetic and molecular approaches to cardiovascular disease$209,018
T32 · FY2012 · HL · contact PI
Saturated Fat and Protein Effects on Atherogenic Dyslipidemia$200,000
R01 · FY2012 · HL · contact PI
Pharmacogenomics and Risk of Cardiovascular Disease$2,595,709
U19 · FY2011 · HL · contact PI
Saturated Fat and Protein Effects on Atherogenic Dyslipidemia$1,457,421
R01 · FY2011 · HL · contact PI
Genetic and molecular approaches to cardiovascular disease$94,479
T32 · FY2011 · HL · contact PI
Pharmacogenomics and Risk of Cardiovascular Disease$2,647,964
U19 · FY2010 · HL · contact PI
Effects of resistant starch on lipid and glucose metabolism in insulin resistance$469,824
RC1 · FY2010 · DK · contact PI
Genetic and molecular approaches to cardiovascular disease$251,156
T32 · FY2010 · HL · contact PI
HMG-CoA reductase alternative splicing and LDL response to statin$200,000
R21 · FY2010 · HL · contact PI
Pharmacogenomics and Risk of Cardiovascular Disease$2,187,093
U01 · FY2009 · HL · contact PI
Effects of resistant starch on lipid and glucose metabolism in insulin resistance$529,746
RC1 · FY2009 · DK · contact PI
Genetic and molecular approaches to cardiovascular disease$240,762
T32 · FY2009 · HL · contact PI
HMG-CoA reductase alternative splicing and LDL response to statin$240,000
R21 · FY2009 · HL · contact PI
Pharmacogenomics and Risk of Cardiovascular Disease$2,850,491
U01 · FY2008 · HL · contact PI
Pharmacogenomics and Risk of Cardiovascular Disease$83,336
U01 · FY2008 · HL · contact PI
Pharmacogenomics and Risk of Cardiovascular Disease$2,935,651
U01 · FY2007 · HL · contact PI
Core--Lipids and Chronic Diseases$83,619
P60 · FY2007 · MD · contact PI
Pharmacogenomics and Risk of Cardiovascular Disease$3,049,802
U01 · FY2006 · HL · contact PI
Core--Lipids and Chronic Diseases$56,035
P60 · FY2006 · MD · contact PI
Pharmacogenomics and Risk of Cardiovascular Disease$3,286,210
U01 · FY2005 · HL
Core--Lipids and Chronic Diseases$56,035
P60 · FY2005 · MD
THE EFFECTS OF NORMALIZING ADIPOSITY ON ATHEROGENIC LIPOPROGEINS IN SUBJECTS$28,623
M01 · FY2005 · RR
Pharmacogenetics Network For Cardiovascular Risk Therapy$2,361,787
U01 · FY2004 · HL
Core--Lipids and Chronic Diseases$56,035
P60 · FY2004 · MD
COMPARATIVE GENOMIC ANALYSIS OF CARDIOVASCULAR GENE REGULATION$5,516
P51 · FY2004 · RR
Pharmacogenetics Network For Cardiovascular Risk Therapy$2,631,545
U01 · FY2003 · HL
COMPARATIVE GENOMIC ANALYSIS OF CARDIOVASCULAR GENE REGU$140,358
U01 · FY2003 · HL
Core--Lipids and Chronic Diseases$50,927
P60 · FY2003 · MD
COMPARATIVE GENOMIC ANALYSIS OF CARDIOVASCULAR GENE REGULATION$3,193
P51 · FY2003 · RR
Pharmacogenetics Network For Cardiovascular Risk Therapy$2,815,461
U01 · FY2002 · HL
COMPARATIVE GENOMIC ANALYSIS OF CARDIOVASCULAR GENE REGU$142,958
U01 · FY2002 · HL
Pharmacogenetics Network For Cardiovascular Risk Therapy$2,538,048
U01 · FY2001 · HL
LIPOPROTEINS AND ATHEROGENESIS IN TRANSGENIC ANIMALS$1,851,517
P01 · FY2001 · HL
COMPARATIVE GENOMIC ANALYSIS OF CARDIOVASCULAR GENE REGU$178,783
U01 · FY2001 · HL
ATHEROGENIC LIPOPROTEIN SUBSPECIES IN TRANSGENIC MICE$0
P01 · FY2001 · HL
LIPOPROTEINS AND ATHEROGENESIS IN TRANSGENIC ANIMALS$1,807,538
P01 · FY2000 · HL
ATHEROGENIC LIPOPROTEIN SUBSPECIES IN TRANSGENIC MICE$358,919
P01 · FY2000 · HL
COMPARATIVE GENOMIC ANALYSIS OF CARDIOVASCULAR GENE REGU$179,956
U01 · FY2000 · HL